1. Dioken DN, Ozgul I, Yilmazbilek I, Yakicier MC, Karaca E, Erson-Bensan AE. An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response. Cancer Immunol Immunother. 2023 Sep 28. doi: 10.1007/s00262-023-03543-y. Epub ahead of print. PMID: 37768345.
  2. Dioken DN, Ozgul I, Koksal Bicakci G, Gol K, Can T, Erson-Bensan AE. Differential expression of mRNA 3'-end isoforms in cervical and ovarian cancers. Heliyon. 2023 Sep 9;9(9):e20035. doi: 10.1016/j.heliyon.2023.e20035. PMID: 37810050; PMCID: PMC10559779.
  3. Cacioppo R, Akman HB, Tuncer T, Erson-Bensan AE, Lindon C. Differential translation of mRNA isoforms underlies oncogenic activation of cell cycle kinase Aurora A. Elife. 2023 Jun 29;12:RP87253. doi: 10.7554/eLife.87253. PMID: 37384380.
  4. Sapmaz A, Erson-Bensan AE. EGFR endocytosis: more than meets the eye. Oncotarget. 2023 Apr 10;14:297-301. doi: 10.18632/oncotarget.28400. PMID: 37036745; PMCID: PMC10085055.
  5. Erdem M, Cicek M, Erson Bensan AE. Versatile RNA: Overlooked gems of the transcriptome. FEBS J. 2023 Jan 31. doi: 10.1111/febs.16742.
  6. Açıkgöz HN, Karaman A, Şahin MA, Çaylan ÖR, Büke GC, Yıldırım E, Eroğlu İC, Erson-Bensan AE, Çetin B, Özer MB. Assessment of silicon, glass, FR4, PDMS and PMMA as a chip material for acoustic particle/cell manipulation in microfluidics. Ultrasonics. 2023 Mar;129:106911. doi: 10.1016/j.ultras.2022.106911. 
  7. Circir A, Koksal Bicakci G, Savas B, Doken DN, Henden ŞO, Can T, Karaca E, Erson-Bensan AE. A C-term truncated EIF2Bγ protein encoded by an intronically polyadenylated isoform introduces unfavorable EIF2Bγ-EIF2γ interactions.Proteins. 2022 Mar;90(3):889-897. doi: 10.1002/prot.26284. Epub 2021 Nov 26.PMID: 34796993
  8. Cicek E, Circir A, Oyken M, Akbulut Caliskan O, Dioken DN, Guntekin Ergun S, Cetin-Atalay R, Sapmaz A, Ovaa H, Sahin O, Erson-Bensan AE. EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers. Oncogene. 2022 Jan;41(2):220-232. doi: 10.1038/s41388-021-02086-9. Epub 2021 Oct 30.PMID: 34718348
  9. Erdem M, Ozgul İ, Dioken DN, Gurcuoglu I, Guntekin Ergun S, Cetin-Atalay R, Can T, Erson-Bensan AE. Identification of an mRNA isoform switch for HNRNPA1 in breast cancersSci Rep. 2021 Dec 27;11(1):24444. doi: 10.1038/s41598-021-04007-y.PMID: 34961772
  10. Erson-Bensan AE. RNA-biology ruling cancer progression? Focus on 3'UTRs and splicing. Cancer Metastasis Rev. 2020 Sep;39(3):887-901. doi: 10.1007/s10555-020-09884-9.PMID: 32361913
  11. Sapmaz A, Berlin I, Bos E, Wijdeven RH, Janssen H, Konietzny R, Akkermans JJ, Erson-Bensan AE, Koning RI, Kessler BM, Neefjes J, Ovaa H. USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7. Nat Commun. 2019 Mar 29;10(1):1454
  12. Beğik O, Öyken M, Çınkıllı T, Can T, Erson-Bensan AE, Alternative Polyadenylation Patterns for Novel Gene Discovery and Classification in Cancer. Neoplasia, 2017, 19(7), 574-582
  13. Erson-Bensan AE, Beğik O, m6A Modification and Implications for microRNAs. MicroRNA, 2017, 6(2), 97-101
  14. Erson-Bensan AE. Alternative polyadenylation and RNA-binding proteins. J Mol Endocrinol. 2016 Aug;57(2):F29-34
  15. Erson-Bensan AE, Can T. Alternative Polyadenylation: Another Foe in Cancer. Mol Cancer Res. 2016 Jun;14(6):507-17
  16. Akman HB, Oyken M, Tuncer T, Can T, Erson-Bensan AE. 3'UTR shortening and EGF signaling: implications for breast cancer. Hum Mol Genet. 2015 Dec 15;24(24):6910-20
  17. Akman HB, Selcuklu SD, Donoghue MT, Akhavantabasi S, Sapmaz A, Spillane C, Yakicier MC, Erson-Bensan AE. ALCAM is indirectly modulated by miR-125b in MCF7 cells. Tumour Biol. 2015 May;36(5):3511-20
  18. Oguz Erdogan AS, Ozdemirler N, Oyken M, Alper M, Erson-Bensan AE. ARID3B expression in primary breast cancers and breast cancer-derived cell lines. Cell Oncol. 2014 Aug;37(4):289-96
  19. Akman HB and Erson-Bensan AE. Noncoding RNAs and Cancer. TJB. 2014;38 (6): 817-828
  20. Akman HB and Erson-Bensan AE. Alternative Polyadenylation and Its Impact on Cellular Processes. MicroRNA 2014; 3(1):2-9
  21. Akman HB, Can T, Erson-Bensan AE.Estrogen-induced upregulation and 3'-UTR shortening of CDC6. Nucleic Acids Res. 2012 Nov 1;40(21):10679-88
  22. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. miR-125b targets ARID3B in breast cancer cells. Cell Structure and Function. 2012; 37(1):27-38
  23. Astarci E, Erson-Bensan AE, Banerjee S. MMP16 expression is downregulated by microRNA-146a in spontaneously differentiating Caco-2 cells. Dev Growth Differ. 2012; 54(2):216-26
  24. Ozek NS, Tuna S, Erson-Bensan AE, Severcan F. Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy. Analyst. 2010 Dec 15; 135(12):3094-102
  25. Keller JA, Erson-Bensan AE and Petty EM, Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer? Cancer Biol Ther.2010 Nov 6;10(9) 942-944
  26. Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM, Erson AE, USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome. 2010 Aug;21(7-8):388-97
  27. Erson AE, Petty EM miRNAs and cancer: New research developments and potential clinical applications, Cancer Biology and Therapy, 2009 Dec; 8 (24): 2317 – 2322
  28. Selcuklu SD, Yakicier MC, Erson AE. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer Genet Cytogenet. 2009 Feb; 189 (1):15-23
  29. Sukas S, Erson AE, Sert C, Kulah H, A parylene based double-channel micro-electrophoresis system for rapid mutation detection via heteroduplex analysis. Electrophoresis. 2008 Sep; 29 (18):3752-3758
  30. Erson AE, Petty EM, miRNAs in disease and development. Clinical Genetics. 2008 Oct; 74(4):296-306
  31. Erson AE, Petty EM. CHFR-associated early G2/M checkpoint defects in breast cancer cells. Molecular Carcinogenesis. 2004 Jan, 39 (1): 26-33
  32. Erson AE, Niell BL, DeMers SK, Rouillard JM, Hanash SM, Petty EM. Overexpressed genes/ESTs and characterization of distinct amplicons on 17q23 in breast cancer cells. Neoplasia. 2001 Nov-Dec,3(6): 521-526
  33. Bespalova IN, Van Camp G, J H Bom S, Brown DJ, Cryns K, DeWan AT, Erson AE, Flothmann K, Kunst HP, Kurnool P, Sivakumaran TA, Cremers CW, Leal SM, Burmeister M, Lesperance MM. Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of low frequency sensorineural hearing loss. Hum Mol Genet. 2001 Oct, 10 (22): 2501-2508
  34. Rouillard JM, Erson AE, Kuick R, Asakawa J, Wimmer K, Muleris M, Petty EM, Hanash S. Virtual genome scan: a tool for restriction landmark-based scanning of the human genome. Genome Res. 2001 Aug, 11(8): 1453-1459

Peer Reviewed Electronic Publications

1. Erdem, M., Özgül, I., Erson-Bensan, A.E, HNRNPA1 (Heterogeneous nuclear ribonucleoprotein A1), 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology, 23(6), pp. 137-142

2. Esra Yavuz, Merve Oyken, Ayse Elif Erson Bensan ALCAM (Activated Leukocyte Cell Adhesion Molecule), 2018; 22(3): 87-92

3. Sapmaz A, Erson-Bensan AE. USP32 (ubiquitin specific peptidase 32). Atlas Genet Cytogenet Oncol Haematol. July 2013

4. Saygili C, Erson-Bensan AE. MIR106B (microRNA 106b). Atlas Genet Cytogenet Oncol Haematol. May 2013

5. Tabasi SA, Erson AE. MIRN221 (microRNA 221). Atlas Genet Cytogenet Oncol Haematol. 2009; 13(8) 562-566

6. Tabasi SA, Erson AE. MIRN222 (microRNA 222). Atlas Genet Cytogenet Oncol Haematol. 2009; 13(8) 566-569

7. Tuna S, Erson AE. MIRN125A (microRNA 125a). Atlas Genet Cytogenet Oncol Haematol. 2009; 13(7) 485-486

8. Tuna S, Erson AE. MIRN125B1 (microRNA 125b-1). Atlas Genet Cytogenet Oncol Haematol. 2009; 13(7) 487-489

9. Akman B, Erson AE. MIRN10B (microRNA 10b). Atlas Genet Cytogenet Oncol Haematol. 2009; 13(5) 360-363

10. Selcuklu SD, Yakicier MC, Erson AE . MIRN21 (microRNA 21). Atlas Genet Cytogenet Oncol Haematol. 2007;11(3) 232-236

11. Erson AE, Petty E M . Kidney: Nephroblastoma (Wilms tumor). Atlas Genet Cytogenet Oncol Haematol. 2007;11(1) 50-53

12. Erson AE, Petty EM. TRIM37 (tripartite motif-containing 37). Atlas Genet Cytogenet Oncol Haematol. 2006;10(4) 239-242

13. Erson AE, Petty EM. TBX2 (T-box 2). Atlas Genet Cytogenet Oncol Haematol. 2005; 9(4) 303-306

14. Erson AE, Petty EM. PLK1 (polo-like kinase 1 (Drosophila)). Atlas Genet Cytogenet Oncol Haematol. 2005; 9(3) 217-220

15. Erson AE, Petty EM. CHFR (Checkpoint with fork-head associated and ring finger) Atlas Genet Cytogenet Oncol Haematol. 2004; 8(3) 219-221

Book Chapters

1. Öyken M, Erson-Bensan AE, microRNAs in Cancer, In: Cancer Molecular Biology. April 2018, Kısayol Yayıncılık, p197-208

2. Erson-Bensan AE, Introduction to MicroRNAs in Biological Systems, In: miRNomics: MicroRNA Biology and Computational Analysis, Series: Methods in Molecular Biology, Edited by Yousef, Malik; Allmer, Jens. Vol. 1107, 2014 XII Humana Press

3. Erson AE, Petty EM, Molecular and genetic events in neoplastic transformation, In: Cancer Epidemiology and Prevention, Edited by David Schottenfeld and Joseph F. Fraumeni, October 2006, Oxford University Press, p47-64

Last Updated:
14/10/2023 - 11:10